Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.

Edoardo Giovanni GianniniLaura BucciFrancesca GarutiMatteo BrunacciBarbara LenziMatteo ValenteEugenio CaturelliGiuseppe CabibboFabio PiscagliaRoberto VirdoneMartina FelderFrancesca CiccareseFrancesco Giuseppe FoschiRodolfo SaccoGianluca Svegliati BaroniFabio FarinatiGian Lodovico RapacciniAndrea OlivaniAntonio GasbarriniMaria Di MarcoFilomena MoriscoMarco ZoliAlberto MasottoFranco BorzioLuisa BenvegnùFabio MarraAntonio ColecchiaGerardo NardoneMauro BernardiFranco Trevisaninull null

Published in: Hepatology (Baltimore, Md.) (2018)

BCLC C stage does not identify patients homogeneous enough to be allocated to a single stage. PS1 alone is not sufficient to include a patient into this stage. The remaining patients should be subclassified according to PS and tumor features, and new patient-tailored therapeutic indications are needed. (Hepatology 2018;67:1784-1796).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors